The drug SI-B001 shows an potential advance in the treatment of relapsed multiple myeloma. The innovative antibody selectively binds to BCMA on myeloma tumors, triggering BCMA-dependent cellular cytotoxicity while https://izalontamab-elisa-facs780920.mpeblog.com/78311951/izalontamab-si-b001-a-hopeful-novel-antibody-approach